Necitumumab - National Cancer Institute

Necitumumab - National Cancer Institute





New Drug for Squamous Non-Small Cell Lung Cancer



A new summary about the drug necitumumab. It was recently approved by the FDA to treat squamous non-small cell lung cancer that has metastasized.

Necitumumab

• 
• 
• 
• 
• 
• 
• 

(NEH-sih-TOO-moo-mab)

This page contains brief information about necitumumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Portrazza

FDA Approved

Yes

FDA Approval for Necitumumab

Use in Cancer

Necitumumab is approved to be used with gemcitabine and cisplatin to treat:

• Squamous non-small cell lung cancer that has metastasized (spread to other parts of the body). It is used as first-line treatment.

Necitumumab is also being studied in the treatment of other types of cancer.

More About Necitumumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Targeted Cancer Therapies - Information about the use of this drug to treat cancer.

Research Results

Lung Cancer Precision Medicine Trials: Adapting to Progress - Information about the use of this drug to treat cancer.

Clinical Trials Accepting Patients

Find Clinical Trials for Necitumumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.